Delirium Market Poised to Surpass USD 522 Million by 2032, Registering a CAGR of 5.45% from 2025-2032

Delirium Market Overview:

The Delirium Market size was valued at USD 348 Million in 2024 and is expected to reach USD 522 Million by 2032, exhibiting a compound annual growth rate (CAGR) of 5.45% during the forecast period (2025-2032). Delirium is an acute neuropsychiatric syndrome characterized by sudden onset of confusion, inattention, and fluctuating levels of consciousness. It commonly affects hospitalized elderly patients and is associated with increased morbidity and mortality. The condition can be triggered by various factors, including infections, surgery, medications, and underlying chronic illnesses.

Download a Free Sample Report Today : https://www.maximizemarketresearch.com/request-sample/273014/

Delirium Market Dynamics

Several factors are propelling the growth of the Delirium Market:

Aging Population: The increasing global geriatric population is a significant driver, as older individuals are more susceptible to delirium due to age-related physiological changes and comorbidities.

Technological Advancements: Innovations in diagnostic tools, such as EEG-based devices and machine learning algorithms, have enhanced the early detection and management of delirium.

Pharmaceutical Developments: The approval of new antipsychotic medications, including long-acting injectables, has expanded treatment options for delirium, improving patient outcomes.

Delirium Market Outlook and Future Trends :

The Delirium Market is expected to witness several key trends:

Integration of Artificial Intelligence (AI): The incorporation of AI in diagnostic processes is anticipated to improve accuracy and efficiency in identifying delirium cases.

Focus on Preventive Care: There is a growing emphasis on preventive strategies, including staff training and patient education, to reduce the incidence of delirium in healthcare settings.

Expansion in Emerging Markets: Developing regions are projected to offer lucrative opportunities due to improving healthcare infrastructure and increased awareness of neuropsychiatric disorders.

Delirium Market Key Recent Developments

The Delirium Market has witnessed notable mergers and acquisitions aimed at enhancing research capabilities and expanding therapeutic portfolios:

United States: In April 2023, Otsuka Pharmaceutical Co., Ltd. received FDA approval for ABILIFY ASIMTUFII (aripiprazole), a medication approved for the treatment of schizophrenia and delirium, as well as for maintenance monotherapy in individuals with bipolar I disorder.

United States: In April 2023, Teva Pharmaceutical Industries obtained FDA approval for UZEDY (risperidone), a long-acting injectable antipsychotic designed to treat schizophrenia and delirium in adults, particularly benefiting physically ill patients by alleviating the behavioral and cognitive symptoms of delirium.

United States: In September 2022, Ceribell, Inc. received FDA breakthrough device designation for its Ceribell system, which uses machine learning to analyze EEG signals, enabling the detection of delirium.

Delirium Market Segmentation

by Type

Hyperactive
Hypoactive
Mixed Source

by Diagnosis

Laboratory Tests
Physical Examination
Imaging test

by Treatment

Antipsychotics
Susupportive care
by End-User Hospitals
Speciality Care
Research Centers

To Gain More Insights into the Market Analysis, Browse Summary of the Research Report : https://www.maximizemarketresearch.com/request-sample/273014/

Some of the current players in theDelirium Market are:

1. Otsuka Pharmaceutical Co., Ltd (Japan)
2. Mylan N.V (US)
3. Teva Pharmaceutical Industries Ltd (Israel)
4. Zydus Group (India)
5. Glenmark Pharmaceuticals Ltd (India)
6. Pfizer (India)
7. Novartis AG (Switzerland)
8. Ceribell, Inc. (United States)
9. Koninklijke Philips N.V. (Netherlands)
10. AbbVie Inc. (United States)

Delirium Market Conclusion :

The Delirium Market is poised for substantial growth, driven by technological advancements, strategic collaborations, and a heightened focus on rare diseases. Continued investment in research and development, along with supportive healthcare policies, is essential to bring innovative therapies to market and improve outcomes for patients affected by this debilitating condition.

For additional reports on related topics, visit our website:

♦ Global Anti-Obesity Prescription Drugs Market https://www.maximizemarketresearch.com/market-report/global-anti-obesity-drugs-market/100768/

♦ Global Systemic Lupus Erythematosus Treatment Market https://www.maximizemarketresearch.com/market-report/global-systemic-lupus-erythematosus-treatment-market/65123/

♦ Global Ovarian Cancer Drugs Market https://www.maximizemarketresearch.com/market-report/global-ovarian-cancer-drugs-market/23883/

Contact Maximize Market Research:

MAXIMIZE MARKET RESEARCH PVT. LTD.
⮝ 3rd Floor, Navale IT park Phase 2,
Pune Banglore Highway, Narhe
Pune, Maharashtra 411041, India.
✆ +91 9607365656
🖂 sales@maximizemarketresearch.com

About Maximize Market Research:

Maximize Market Research is one of the fastest-growing market research and business consulting firms serving clients globally. Our revenue impact and focused growth-driven research initiatives make us a proud partner of majority of the Fortune 500 companies. We have a diversified portfolio and serve a variety of industries such as IT & telecom, chemical, food & beverage, aerospace & defense, healthcare and others.

This release was published on openPR.